These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
76 related items for PubMed ID: 11027421
1. Treatment options for the cutaneous manifestations of systemic sclerosis. Dutz J. Skin Therapy Lett; 2000; 6(1):3-5. PubMed ID: 11027421 [Abstract] [Full Text] [Related]
2. Diagnosis and management of scleroderma peripheral vascular disease. Herrick A. Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535 [Abstract] [Full Text] [Related]
3. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. Strange G, Nash P. Int J Rheum Dis; 2009 Sep; 12(3):192-206. PubMed ID: 20374346 [Abstract] [Full Text] [Related]
4. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. Abou-Raya A, Abou-Raya S, Helmii M. J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692 [Abstract] [Full Text] [Related]
10. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Henness S, Wigley FM. Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543 [Abstract] [Full Text] [Related]
11. Scleroderma--clinical and pathological advances. Denton CP, Black CM. Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741 [Abstract] [Full Text] [Related]
14. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment]. Sicińska J, Rudnicka L. Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347 [Abstract] [Full Text] [Related]
15. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM, Scleroderma Clinical Trials Consortium. Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489 [Abstract] [Full Text] [Related]
16. Targeted therapy for systemic sclerosis. Steen V. Autoimmun Rev; 2006 Feb; 5(2):122-4. PubMed ID: 16431341 [Abstract] [Full Text] [Related]
17. Localized and systemic scleroderma. Hawk A, English JC. Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134 [Abstract] [Full Text] [Related]
18. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE, OMERACT 6. J Rheumatol; 2003 Jul; 30(7):1630-47. PubMed ID: 12858472 [Abstract] [Full Text] [Related]